Positive Health Online
Your Country
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: https://peacegifts.shop/]](/img/original/BannerAvatar/3906.e1d1ebc07ce7530bbb3d6cf426966b6f.jpg "https://peacegifts.shop/")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: BUSTAMANTE and COLLEAGUES,
Listed in Issue 228
Abstract
BUSTAMANTE and COLLEAGUES, (1)Servei de Neurología/Neuroimmunología. Centre d'Esclerosi Múltiple de Catalunya, Cemcat. Hospital Universitari Vall dHebron (HUVH), Barcelona, Spain investigated whether the type I interferon (IFN) signalling pathway is up-regulated in isolated monocytes from interferon-beta (IFNb) non-responders and searched for additional biological pathways involved in the response to IFNb treatment.
Background
A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients do not respond to interferon-beta (IFNb) treatment. In previous studies with peripheral blood mononuclear cells (PBMC), we identified a subgroup of IFNb non-responders that was characterized by a baseline over-expression of type I IFN inducible genes. Additional mechanistic experiments carried out in IFNb non-responders suggested a selective alteration of the type I IFN signalling pathway in the population of blood monocytes. Here, we aimed (i) to investigate whether the type I IFN signalling pathway is up-regulated in isolated monocytes from IFNb non-responders at baseline; and (ii) to search for additional biological pathways in this cell population that may be implicated in the response to IFNb treatment.
Methodology
Twenty RRMS patients classified according to their clinical response to IFNb treatment and 10 healthy controls were included in the study. Monocytes were purified from PBMC obtained before treatment by cell sorting and the gene expression profiling was determined with oligonucleotide microarrays.
Results
Purified monocytes from IFNb non-responders were characterized by an over-expression of type I IFN responsive genes, which confirms the type I IFN signature in monocytes suggested from previous studies. Other relevant signalling pathways that were up-regulated in IFNb non-responders were related with the mitochondrial function and processes such as protein synthesis and antigen presentation, and together with the type I IFN signalling pathway, may also be playing roles in the response to IFNb.
Conclusion
References
Bustamante MF(1), Nurtdinov RN, Río J, Montalban X, Comabella M. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. PLoS One 8(4):e60994. Apr 18 2013. doi: 10.1371/journal.pone.0060994. Print 2013.
